biostudies-literatureFayad LNCI NIH HHS573-83https://www.ebi.ac.uk/biostudies/studies/S-EPMC4878046biostudies-literatureUnknown31(5)<h4>Purpose</h4>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL).<h4>Patients and methods</h4>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.<h4>Results</h4>In all, 118 Journal of clinical oncology : official journal of the American Society of Clinical OncologySafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.PMC4878046P30 CA016672Rohatiner AHess GJohnson PKneissl MHua SYSmith MRAdvani ALuu KTVerhoef GKaufman JLDang NHForan JOffner FCzuczman MDurrant SCoiffier BVandendries EFayad LGine EBoni JfalseSafety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.<h4>Purpose</h4>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL).<h4>Patients and methods</h4>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.<h4>Results</h4>In all, 118 2013-01-01T00:00:00Z2013 Feb2025-04-19T12:31:21.6Z2019-03-27T02:14:24ZS-EPMC48780462329579010.1200/JCO.2012.42.721110.1200/jco.2012.42.7211